About Us

Synlogic is developing a new class of living, Synthetic Biotic™ medicines

At Synlogic, we are dedicated to bringing innovative living medicines to patients by using the tools and principles of synthetic biology to genetically re-program beneficial bacteria.

Using our Synthetic Biotic platform, we are developing engineered probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these living, Synthetic Biotic medicines orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver Synthetic Biotic medicines at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors.

We can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). We are also engaged in research and development of Synthetic Biotic medicines to address more prevalent conditions, including inflammatory bowel disease (IBD) as part of our collaboration with AbbVie, cancer and metabolic conditions such as diabetes and obesity.

Synlogic is led by industry veterans who have pioneered new therapeutic approaches, commercialized drugs and built companies. We are fortunate to be backed by leading life sciences investors, including Atlas Venture, New Enterprise Associates (NEA), the Bill & Melinda Gates Foundation, Orbimed and Deerfield Management.